1038924-65-0

Basic information

• Product Name: (S)-5-[(Biphenyl-4-yl)methyl]-1-(2,2-dimethylpropionyl)pyrrolidin-2-one
• Synonyms: (S)-5-[(Biphenyl-4-yl)methyl]-1-(2,2-dimethylpropionyl)pyrrolidin-2-one;LCZ696 intermediate D;(S)-5-([1,1-Biphenyl]-4-ylmethyl)-1-pivaloylpyrrolidin-2-one
• CAS NO: 1038924-65-0
• Molecular Formula: C₂₂H₂₅NO₂
• Molecular Weight: 335.4394
• EINECS: -0
• Mol File: 1038924-65-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 498.7±24.0 °C(Predicted)
• Appearance: /
• Density: 1.115±0.06 g/cm3(Predicted)
• PKA: -1.58±0.40(Predicted)
• CAS DataBase Reference: (S)-5-[(Biphenyl-4-yl)methyl]-1-(2,2-dimethylpropionyl)pyrrolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-5-[(Biphenyl-4-yl)methyl]-1-(2,2-dimethylpropionyl)pyrrolidin-2-one(1038924-65-0)
• EPA Substance Registry System: (S)-5-[(Biphenyl-4-yl)methyl]-1-(2,2-dimethylpropionyl)pyrrolidin-2-one(1038924-65-0)

Safety Data

• Hazardous Substances Data: 1038924-65-0(Hazardous Substances Data)

Usage

General Description

(S)-5-[(Biphenyl-4-yl)methyl]-1-(2,2-dimethylpropionyl)pyrrolidin-2-one is a chemical compound with a complex structure. It belongs to the class of pyrrolidinones, which are commonly used in the pharmaceutical industry as building blocks for various drugs. This specific compound contains a pyrrolidinone core with a biphenyl-4-ylmethyl group and a 2,2-dimethylpropionyl group. It may have potential applications in medicinal chemistry and drug development due to its structural features and potential pharmacological properties. However, further research and evaluation are needed to fully understand its biological activities and potential therapeutic uses.

Upstream product

• 1383026-42-3 [(S)-2-biphenyl-4-yl-1-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-ylmethyl)ethyl]carbamic acid t-butyl ester 
• 1383026-37-6 [(R)-1-biphenyl-4-ylmethyl-2-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-2-oxoethyl]carbamic acid t-butyl ester 
• 1038924-77-4 (S)-2-biphenyl-4-ylmethyl-5-oxopyrrolidine-1-carboxylic acid tert-butyl ester 
• 128779-47-5 (2R)-3-(biphenyl-4-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 1038924-61-6 (S)-5-biphenyl-4-ylmethylpyrrolidin-2-one 
• 3282-30-2 pivaloyl chloride 

Downstream Products

• 1038924-79-6 (3S,5S)-5-biphenyl-4-ylmethyl-3-methyl-2-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1038924-76-3 (3R,5S)-5-biphenyl-4-ylmethyl-3-methyl-2-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1038924-66-1 (3R,5S)-5-biphenyl-4-ylmethyl-1-(2,2-dimethylpropionyl)-3-methylpyrrolidin-2-one 
• 1038924-67-2 (3S,5S)-5-biphenyl-4-ylmethyl-1-(2,2-dimethylpropionyl)-3-methylpyrrolidin-2-one 
• 1383027-09-5 (3R,5R)-5-Biphenyl-4-ylmethyl-1-(2,2-dimethylpropionyl)-3-hydroxypyrrolidin-2-one 
• 1383005-20-6 (2R,4R)-4-[(5-acetyl-2H-pyrazole-3-carbonyl)amino]-5-biphenyl-4-yl-2-hydroxypentanoic acid ethyl ester trifluoroacetate 
• 1383005-25-1 (2R,4R)-4-[(5-acetyl-2H-pyrazole-3-carbonyl)amino]-5-biphenyl-4-yl-2-hydroxypentanoic acid trifluoroacetate 
• 1383005-31-9 (2R,4R)-4-[(5-acetyl-2H-pyrazole-3-carbonyl)amino]-5-biphenyl-4-yl-2-hydroxypentanoic acid butyl ester trifluoroacetate 
• 1383005-80-8 5-((1R,3R)-1-biphenyl-4-ylmethyl-3-butoxycarbonyl-3-hydroxy-propylcarbamoyl)-1H-pyrazole-3-carboxylic acid trifluoroacetate 
• 1383006-00-5 (2R,4R)-4-{[5-(azetidine-1-carbonyl)-2H-pyrazole-3-carbonyl]amino}-5-biphenyl-4-yl-2-hydroxypentanoic acid ethyl ester trifluoroacetate 
• 1383006-09-4 (2R,4R)-4-{[5-(azetidine-1-carbonyl)-2H-pyrazole-3-carbonyl]amino}-5-biphenyl-4-yl-2-hydroxypentanoic acid trifluoroacetate 
• 1383006-19-6 (2R,4R)-5-biphenyl-4-yl-2-hydroxy-4-{[5-(pyrrolidine-1-carbonyl)-2H-pyrazole-3-carbonyl]amino}pentanoic acid ethyl ester trifluoroacetate 
• 1383006-26-5 (2R,4R)-5-biphenyl-4-yl-2-hydroxy-4-{[5-(pyrrolidine-1-carbonyl)-2H-pyrazole-3-carbonyl]amino}pentanoic acid trifluoroacetate 
• 1383006-34-5 (2R,4R)-5-biphenyl-4-yl-2-hydroxy-4-[(2-hydroxypyrimidine-5-carbonyl)amino]pentanoic acid ethyl ester trifluoroacetate 

Relevant articles and documents

NITRIC OXIDE DONOR NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R7, R8, Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donors and have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

NEW PROCESS

-